Uncategorized

Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives

Enveric Biosciences today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,746,087, titled “C-4 Carboxylic Acid Substituted Tryptamine Derivatives and Methods of Using,” pertaining to the Company’s EVM201 Series and lead candidate EB-373, a psilocin prodrug being developed for the treatment of anxiety disorder.

Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives Read More »

Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer

Sinovac Biotech Ltd. announced that its Board of Directors unanimously determined that the partial tender offer by Alternative Liquidity Index LP to acquire up to 10,000,000 common shares of Sinovac for $0.03 per share in cash is NOT advisable and is NOT in the best interests of the Company or its shareholders.

Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer Read More »

First Patient with NyokAssist™ Interventional Ventricular Assist Device: Dr. Junbo Ge’s team successfully completed the first high-risk PCI treatment supported by the new generation of interventional VAD

Recently, NyokAssist™ was first-in-man use, supporting High-risk PCI completed by Dr. Junbo Ge’s team from Zhongshan Hospital in Shanghai.

First Patient with NyokAssist™ Interventional Ventricular Assist Device: Dr. Junbo Ge’s team successfully completed the first high-risk PCI treatment supported by the new generation of interventional VAD Read More »

Scroll to Top